Tenderwize
Back to tender search

Open-house rebate agreement for Ublituximab

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 195 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Ublituximab, ATC L04AG14

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

46 / 100

Complexity

58 / 100

Risk factors

Submission by original document is required and electronic submission is not allowed, which increases the risk of late...

The buyer reserves the right to replace the open-house contracts with exclusive rebate agreements during the term, whic...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive rebate agreements for pharmaceutical products containing Ublituximab (ATC L04AG14).
  • Open-house model with uniform conditions for all participants and no individual negotiations.
Show full summary

Open-house supply arrangement for the active substance Ublituximab (ATC L04AG14) offered by AOK Rheinland-Pfalz/Saarland. It is a non-exclusive, no-selection contract model with uniform terms for all participants, no individual negotiations, and monthly entry possible during the 24-month term. The notice states that this publication is not a public contract in the sense of procurement law, but it is published in TED for transparency. No contract value is provided.

Risks

Submission by original document is required and electronic submission is not allowed, which increases the risk of late...

The buyer reserves the right to replace the open-house contracts with exclusive rebate agreements during the term, whic...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Only authorised and legally marketable medicines in Germany may be supplied.

Administrative

  • If a medicine is not yet listed in Lauer-Taxe at submission time, an AMIce public extract must be provided.
  • The AMIce extract must show name, marketing authorisation holder or authorised manufacturer, dosage form, active substance, and marketability.

Buyer

Lots (1)

LOT-0001

Open-house rebate agreement for Ublituximab

Single lot covering non-exclusive pharmaceutical rebate agreements for medicines containing Ublituximab. The open-house model applies uniform terms to all participating pharmaceutical companies. Children’s medicines listed in the BfArM list under Section 35(5a) SGB V are excluded. Contract start is earliest 2025-05-01, with monthly entry possible during the 24-month period; contracts end no later than 24 months after the earliest start date. The lot information comes from structured data and the TED XML notice.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

Apr 2025 - Apr 2027

Category

Pharmaceutical products

Deadline

Deadline Feb 28, 2027

Procurement Details

Publication date
26 Mar 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
196730-2025

Documents (1)

Similar tenders